Hoth Therapeutics Inc - ESG Rating & Company Profile powered by AI
This ESG score includes seventeen UN SDGs including: 'Quality Education', 'Decent Work & Economic Growth' and 'Partnerships for the Goals'. This ESG score for Hoth Therapeutics Inc represents its transparency towards the UN SDGs. If you work at Hoth Therapeutics Inc and you wish to licence your ESG aseessment, please get in touch.
Hoth Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.2; made up of an environmental score of 8.0, social score of 2.7 and governance score of 8.0.
6.2
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
427 | Scancell Holdings PLC | 6.3 | High |
427 | Verastem Inc | 6.3 | High |
450 | Hoth Therapeutics Inc | 6.2 | High |
450 | Cannasouth Ltd | 6.2 | High |
450 | CareDx International AB | 6.2 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Hoth Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Hoth Therapeutics Inc disclose current and historical energy intensity?
Does Hoth Therapeutics Inc report the average age of the workforce?
Does Hoth Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Hoth Therapeutics Inc disclose its ethnicity pay gap?
Does Hoth Therapeutics Inc disclose cybersecurity risks?
Does Hoth Therapeutics Inc offer flexible work?
Does Hoth Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Hoth Therapeutics Inc disclose the number of employees in R&D functions?
Does Hoth Therapeutics Inc conduct supply chain audits?
Does Hoth Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Hoth Therapeutics Inc conduct 360 degree staff reviews?
Does Hoth Therapeutics Inc disclose the individual responsible for D&I?
Does Hoth Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Hoth Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Hoth Therapeutics Inc disclose water use targets?
Does Hoth Therapeutics Inc have careers partnerships with academic institutions?
Did Hoth Therapeutics Inc have a product recall in the last two years?
Does Hoth Therapeutics Inc disclose incidents of discrimination?
Does Hoth Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Hoth Therapeutics Inc issued a profit warning in the past 24 months?
Does Hoth Therapeutics Inc disclose parental leave metrics?
Does Hoth Therapeutics Inc disclose climate scenario or pathway analysis?
Does Hoth Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Hoth Therapeutics Inc disclose the pay ratio of women to men?
Does Hoth Therapeutics Inc support suppliers with sustainability related research and development?
Does Hoth Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Hoth Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Hoth Therapeutics Inc involved in embryonic stem cell research?
Does Hoth Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Hoth Therapeutics Inc disclose its waste policy?
Does Hoth Therapeutics Inc report according to TCFD requirements?
Does Hoth Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Hoth Therapeutics Inc disclose energy use targets?
Does Hoth Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Hoth Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Hoth Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.